Vanadium: A Panacea for Resistance to Oncolytic Immunotherapy? - Wikidata - awgldk - TriplyDB

Vanadium: A Panacea for Resistance to Oncolytic Immunotherapy?

Vanadium: A Panacea for Resistance to Oncolytic Immunotherapy?

http://www.wikidata.org/entity/Q49715030

about

Vanadium: A Panacea for Resistance to Oncolytic Immunotherapy?

http://www.wikidata.org/entity/Q49715030

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Vanadium: A Panacea for Resistance to Oncolytic Immunotherapy?

@en

Vanadium: A Panacea for Resistance to Oncolytic Immunotherapy?

@nl

type

label

Vanadium: A Panacea for Resistance to Oncolytic Immunotherapy?

@en

Vanadium: A Panacea for Resistance to Oncolytic Immunotherapy?

@nl

prefLabel

Vanadium: A Panacea for Resistance to Oncolytic Immunotherapy?

@en

Vanadium: A Panacea for Resistance to Oncolytic Immunotherapy?

@nl

P1433

Q49715030-2B38E4A0-3EAC-4FC1-A54F-8033FC008F14

P1476

Q49715030-69E72F08-0E6B-4ECC-B14F-8C0F6ADFEDC9

P2093

Q49715030-158431CC-D755-407B-A240-B1D6B9B778FA

P2860

Q49715030-0BBB8BD4-A449-4CFF-8657-7FE338CFCA9E

Q49715030-3290EDCF-DCB7-42E1-8668-EA6A5BB7C685

Q49715030-53A8264D-D639-4D17-8EDF-CB707F418E70

Q49715030-60CA5C7B-5C77-41F5-8684-7C35DBC1FE4C

Q49715030-6284262A-77CC-440D-9D54-2E74F734428D

Q49715030-674A3488-38FE-451E-98AA-27F363F77F95

Q49715030-92358BC5-D5C2-479D-97DA-AFCACA95673E

Q49715030-B7DBCB51-ED7A-46A7-9DC2-A6A5CC55778E

Q49715030-BD67FEA3-E2E8-417D-9132-B8555E7F6F0E

Q49715030-BE8FC686-5426-4905-BCCB-EE3B3A3F4131

P304

Q49715030-BB8FDD32-9E4E-406F-9479-59F9759A589B

P31

Q49715030-C00FCA80-50A8-4903-9FE0-77CB317E5952

Q49715030-a7920891-d2a8-4d8c-8d34-0d3e242b64a7

P356

Q49715030-C851E9C9-08E5-4B5F-ADE3-9988AA2397C2

P433

Q49715030-C7312432-6C37-4AB6-B6A1-6DBF6B5C19C9

P478

Q49715030-961EBCAD-1375-426B-8958-72F09AD99585

P577

Q49715030-DA8A9BCB-0F97-4BD3-B65A-2AE278D7D871

P698

Q49715030-B1369AE9-958F-4C05-8C41-CD503431D066

P921

Q49715030-2536C442-FCBF-4BEC-8408-C1D072A1D3FC

P932

Q49715030-634E9F58-9C69-425A-A1FF-7211931686DE

P356

J.YMTHE.2017.12.006

P1433

Molecular Therapy

P1476

Vanadium: A Panacea for Resistance to Oncolytic Immunotherapy?

@en

P2093

Dmitriy Zamarin

http://www.w3.org/2001/XMLSchema#string

P2860

Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells

Type I interferon is selectively required by dendritic cells for immune rejection of tumors

Protein tyrosine phosphatases and the immune response

Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

The chemistry and biochemistry of vanadium and the biological activities exerted by vanadium compounds.

Vanadium in diabetes: 100 years from Phase 0 to Phase I.

Maraba virus as a potent oncolytic vaccine vector.

Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma.

SHP-1: the next checkpoint target for cancer immunotherapy?

P304

9-12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.YMTHE.2017.12.006

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29249394

http://www.w3.org/2001/XMLSchema#string

P921

P932

5763147

http://www.w3.org/2001/XMLSchema#string